

150-Patient Clinical Study of Seracam® Portable Hybrid Gamma-Optical Camera Presented at EANM'26

London, UK, 19th October 2026. Serac Imaging Systems Limited, the medtech company developing 'Seracam®' a portable hybrid gamma-optical camera for medical imaging, and its clinical investigators from the Faculty of Medicine at Universiti Malaya, Malaysia, announce that an e-poster reporting a completed 150-patient clinical study of Seracam® in routine nuclear medicine practice at the Universiti Malaya Medical Centre is being presented at the European Association of Nuclear Medicine (EANM) Annual Congress. The congress is taking place from 17th to 21st October 2026 at the Austria Center Vienna, Austria.

The e-poster (number EP-1071), titled **"Clinical application of a novel SFOV hybrid optical-gamma camera in the nuclear medicine clinic"**, is available during congress opening hours. SFOV refers to small field-of-view imaging, used for small organs and targeted areas of the body. The study follows the first clinical results from Universiti Malaya presented at EANM'24.

Key facts	
Study	Prospective pilot study, 150 patients, completed
Site	Universiti Malaya Medical Centre, Kuala Lumpur, Malaysia
Device	Seracam, a portable small field-of-view (SFOV) hybrid gamma-optical camera
Radionuclides	Technetium-99m, iodine-131 and yttrium-90
Comparator	Standard-of-care gamma camera imaging
Applications	Thyroid and parathyroid imaging, sentinel node localisation and Y-90 microsphere therapy imaging
Presented	EANM'26, Austria Center Vienna, 17 to 21 October 2026, e-poster EP-1071
Regulatory status	Investigational use only

Patients undergoing routine nuclear medicine procedures with technetium-99m, iodine-131 and yttrium-90 were imaged with Seracam alongside standard-of-care gamma camera imaging. Images were compared qualitatively, and integration into routine clinical workflows was assessed through direct observation and structured operator feedback.

The investigators reported that:

- Seracam demonstrated good agreement with standard-of-care imaging
- The compact, portable design allowed use in confined clinical environments without disrupting routine workflows
- Real-time optical image overlay and integrated LED lighting supported camera positioning and intuitive localisation of radiotracer uptake

- Software-controlled collimator switching allowed a flexible balance between sensitivity and resolution for optimal imaging
- A short learning curve was observed for camera positioning and collimator selection
- Applications included thyroid and parathyroid imaging, sentinel node localisation and Y-90 microsphere therapy, with potential for interventional and surgical guidance

The investigators concluded that the camera is a feasible complementary imaging tool in nuclear medicine, with potential for bedside nuclear medicine imaging and for use in interventional and intraoperative settings beyond conventional imaging suites. Further studies are planned to evaluate quantitative performance, clinical impact and the optimisation of hybrid imaging and surgical workflows.

Dr Aik Hao Ng, clinical medical physicist and senior lecturer at Universiti Malaya, said:

“Using Seracam with 150 patients across a wide range of routine procedures and different radionuclides has given our clinical team extensive and valuable hands-on experience. Seeing radiotracer uptake in real time, fused with the patient’s anatomy at the point of imaging, has given us a clearer understanding of how hybrid imaging can be incorporated into clinical practice. We look forward to building on this experience in further studies, including in a surgical setting.”

Mark Rosser, Chief Executive of Serac Imaging Systems, added:

“This is the largest clinical study of Seracam to date, and we are grateful to Dr Ng and the team at the Universiti Malaya Medical Centre for their dedication in completing it. We are highly encouraged that Seracam fitted easily into everyday clinical workflows, with images in good agreement with standard-of-care imaging. We believe Seracam has the potential to make molecular imaging more accessible at the point of care, with potential benefits for both clinical teams and patients.”

The e-poster is authored by Aik Hao Ng, Muhammad Ikhmal Sofian, Intan Noorliyana Md Musidek and Mohammad Nazri Md Shah of the Faculty of Medicine at Universiti Malaya, Chai Hong Yeong of Taylor’s University, Malaysia, and Alan C. Perkins of the School of Medicine, University of Nottingham.

- ENDS -

Seracam is for investigational use only and has not been registered or approved by the FDA, UK, European or Malaysian regulatory authorities.

For more information, please contact:

Mark Rosser, Chief Executive Officer +44 (0)20 8948 0000
info@seraclifesciences.com

Francetta Carr, Communications Director +44 (0)7711 010 820
francettacarr@seraclifesciences.com

Follow us on LinkedIn: www.linkedin.com/company/seracimagingssystems

Notes to Editors

Abstract EP-1071 is published in the EANM’26 Abstracts Book: [https://doi.org/10.1016/S3051-2913\(26\)00285-5](https://doi.org/10.1016/S3051-2913(26)00285-5)

Poster is available on request.

About EANM'26: <https://eanm.org/congress-scientific-events/eanm26/>

About Serac Imaging Systems and Seracam®

Serac Imaging Systems Ltd is a medtech company developing a portable hybrid gamma-optical camera for medical imaging. Our lead product is Seracam® which is in development to bring the benefits of high-resolution molecular imaging to a patient's bedside, instead of being confined for use in a hospital's nuclear medicine imaging department. A further unique feature of this technological approach is the overlay of a gamma image with an optical image of the same anatomical location under examination. Such portable and enhanced imaging technology has the potential to help clinicians make better, more informed and more timely treatment decisions. For further details, please see www.seracimagingssystems.com

Seracam is a UK and EU registered trademark. Serac Imaging Systems Ltd is a wholly owned subsidiary of Serac Life Sciences Limited.

Related release: [First Clinical Results Using Seracam® for Small Organ Imaging Presented at EANM'24](#); 23 October 2024

Frequently asked questions

What is Seracam?

Seracam is a portable hybrid gamma-optical camera in development by Serac Imaging Systems for nuclear medicine and molecular imaging. It is designed for small field-of-view imaging at the point of care, including at the patient's bedside.

What is a hybrid gamma-optical camera?

It is a camera that detects gamma rays emitted by a radiotracer and records a standard optical image of the same area at the same time. The two images are overlaid in real time, showing where radiotracer uptake is located in relation to the patient's anatomy.

What did the Universiti Malaya study evaluate?

The prospective pilot study evaluated the first clinical application of Seracam in 150 patients undergoing routine nuclear medicine procedures at the Universiti Malaya Medical Centre. Seracam images were compared qualitatively with standard-of-care gamma camera images, and integration into clinical workflows was assessed through observation and operator feedback.

Which nuclear medicine procedures were included?

Procedures used technetium-99m, iodine-131 and yttrium-90. Applications reported include thyroid and parathyroid imaging, sentinel node localisation and bone spot imaging.

What does small field-of-view (SFOV) mean?

Small field-of-view cameras image a limited area of the body, such as the thyroid or a lymph node.

Is Seracam approved for clinical use?

No. Seracam is for investigational use only and has not been registered or approved by the FDA, UK, European or Malaysian regulatory authorities.

What are the next steps?

The investigators plan further studies to evaluate quantitative performance, clinical impact and the optimisation of hybrid imaging and surgical workflows.

About molecular imaging

Molecular imaging is a type of medical imaging that provides unique insights into what is happening inside the body at the cellular and molecular level helping physicians to deliver personalised medicine by delivering the right treatment to the right patient at the right time. Unlike other medical imaging technologies such as x-rays, computed tomography (CT) and ultrasound (US) which provide structural images, molecular imaging allows physicians to see how cells, tissues and organs are functioning and to measure chemical and biological processes without having to resort to biopsy or surgery.